Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients

N/ACompletedNCT01936051

Seoul National University Hospital12 enrolled

Overview

To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma concentration and the transporter occupancy from OCD patients treated with escitalopram. To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram.

To measure plasma concentration of escitalopram in OCD patients treated with escitalopram. To measure serotonin transporter occupancy by escitalopram in OCD patients treated with escitalopram. To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram.

Study Type

OBSERVATIONAL

Enrollment

Conditions

OCD

Eligibility

Sex: MALEMin age: 20 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of OCD based on Diagnostic and Statistical Manual(DSM)-IV criteria * no change of escitalopram dosage in 6 weeks Exclusion Criteria: * psychiatric comorbidity other than OCD * History of head injury, epilepsy, other general medical disorder

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

serotonin transporter occupancy

Time frame: 72hr after oral administration of escitalopram

Secondary Outcomes

genotype

Time frame: baseline

Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score

scale for the severity of Obsessive-compulsive symptoms

Time frame: baseline

serotonin transporter occupancy

serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram

Time frame: within the first 24hrs after oral administration of escitalopram

escitalopram plasma concentration

plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram

Time frame: within 72 hours after oral administration of escitalopram

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.